Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bellet

Showing results (141-150 of 151) with videos related to

Pageof 16
Sort By:
Nature Medicine|June 24, 2018
Author Correction: Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosisLuigina Romani, Vasilis Oikonomou, Silvia Moretti, et al.
ESMO Open|January 4, 2025
Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)E Agostinetto, G Pfeiler, D Hlauschek, et al.
ESMO Open|October 1, 2024
Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES studyÁ Guerrero-Zotano, J M Pérez-García, M Ruiz-Borrego, et al.
American Journal of Respiratory Cell and Molecular Biology|October 17, 2022
Aryl Hydrocarbon Receptor Agonism Antagonizes the Hypoxia-driven Inflammation in Cystic FibrosisMarilena Pariano, Matteo Puccetti, Claudia Stincardini, et al.
Infection and Immunity|March 30, 2021
Pharyngeal Microbial Signatures Are Predictive of the Risk of Fungal Pneumonia in Hematologic PatientsClaudio Costantini, Emilia Nunzi, Angelica Spolzino, et al.
Breast Cancer Research and Treatment|April 1, 2024
First-line therapy with palbociclib in patients with advanced HR<sup>+</sup>/HER2<sup>-</sup> breast cancer: The real-life study PALBOSPAINN Martínez-Jañez, M Bellet Ezquerra, L M Manso Sanchez, et al.
The Journal of Clinical Investigation|November 30, 2021
Anakinra restores cellular proteostasis by coupling mitochondrial redox balance to autophagyFrank L van de Veerdonk, Giorgia Renga, Marilena Pariano, et al.
Breast Cancer Research : BCR|January 24, 2025
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])A DeMichele, A C Dueck, D Hlauschek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2023
Genomic characterisation of hormone receptor-positive breast cancer arising in very young womenS J Luen, G Viale, S Nik-Zainal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)E L Mayer, D Hlauschek, M Gnant, et al.
Pageof 16

Showing results (141-150 of 151) with videos related to

Sort By:
Pageof 16
Nature Medicine|June 24, 2018
Author Correction: Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosisLuigina Romani, Vasilis Oikonomou, Silvia Moretti, et al.
ESMO Open|January 4, 2025
Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)E Agostinetto, G Pfeiler, D Hlauschek, et al.
ESMO Open|October 1, 2024
Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES studyÁ Guerrero-Zotano, J M Pérez-García, M Ruiz-Borrego, et al.
American Journal of Respiratory Cell and Molecular Biology|October 17, 2022
Aryl Hydrocarbon Receptor Agonism Antagonizes the Hypoxia-driven Inflammation in Cystic FibrosisMarilena Pariano, Matteo Puccetti, Claudia Stincardini, et al.
Infection and Immunity|March 30, 2021
Pharyngeal Microbial Signatures Are Predictive of the Risk of Fungal Pneumonia in Hematologic PatientsClaudio Costantini, Emilia Nunzi, Angelica Spolzino, et al.
Breast Cancer Research and Treatment|April 1, 2024
First-line therapy with palbociclib in patients with advanced HR<sup>+</sup>/HER2<sup>-</sup> breast cancer: The real-life study PALBOSPAINN Martínez-Jañez, M Bellet Ezquerra, L M Manso Sanchez, et al.
The Journal of Clinical Investigation|November 30, 2021
Anakinra restores cellular proteostasis by coupling mitochondrial redox balance to autophagyFrank L van de Veerdonk, Giorgia Renga, Marilena Pariano, et al.
Breast Cancer Research : BCR|January 24, 2025
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])A DeMichele, A C Dueck, D Hlauschek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2023
Genomic characterisation of hormone receptor-positive breast cancer arising in very young womenS J Luen, G Viale, S Nik-Zainal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)E L Mayer, D Hlauschek, M Gnant, et al.
Pageof 16